Request support

STAY INFORMED AND CONNECTED

Learn more about neffy—for your patients with type I allergic reactions

Request information by checking the appropriate box[es] below:

Please select at least one checkbox below.

Connect me with a company specialist to learn more about neffy

I want to receive additional information and support from BlinkRx related to the neffy support program, neffyconnect, available to patients through BlinkRx

I would like to order neffy demonstration devices

I would like to order a neffy carrying case

I would like to receive patient support materials for neffy

I would like to receive updates on the neffyinSchools program

*Required fields.

Title

First name*Please enter your first name.

Last name*Please enter your last name.

Email address*Please enter a valid email address.

Phone number

Are you a*

Please select an option.

NPI number*Please enter your NPI number.

Practice name

Address 1*Please enter your address.

Address 2

City*Please enter your city.

ZIP code*Please enter a ZIP code.

*By clicking "SUBMIT" below, I certify that I am 18 years of age or older and consent to allow ARS Pharmaceuticals Operations, Inc. and its agents and representatives (“ARS Pharma”) to send me information and resources about the product, condition, support services, and other relevant topics. I also understand that ARS Pharma may use my information to contact me to provide resources related to products, diseases, and other areas of interest. Learn more about how ARS Pharma handles your personal information by reviewing our Privacy Policy. Learn more about the legal terms that govern your use of our websites by reviewing our Terms of Use.

This field is required.

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION

neffy is indicated for emergency treatment of type I allergic reactions, including anaphylaxis, in adult and pediatric patients aged 4 years and older who weigh 15 kg or greater.

IMPORTANT SAFETY INFORMATION

It is recommended that patients are prescribed and have immediate access to two neffy nasal sprays at all times. In the absence of clinical improvement or if symptoms worsen after initial treatment, administer a second dose of neffy in the same nostril with a new nasal spray starting 5 minutes after the first dose.

neffy is for use in the nose only.

Advise patients when to seek emergency medical assistance for close monitoring of the anaphylactic episode and in the event further treatment is required.

Absorption of neffy may be affected by underlying structural or anatomical nasal conditions.

Administer with caution to patients who have heart disease; epinephrine may aggravate angina pectoris or produce ventricular arrhythmias. Arrhythmias, including fatal ventricular fibrillation, have been reported, particularly in patients with underlying cardiac disease or taking cardiac glycosides, diuretics, or anti-arrhythmics.

The presence of a sulfite in neffy should not deter use.

neffy may alter nasal mucosa for up to 2 weeks after administration and increase systemic absorption of nasal products, including neffy.

Patients with certain medical conditions or who take certain medications for allergies, depression, thyroid disorders, diabetes, and hypertension, may be at greater risk for adverse reactions.

Epinephrine can temporarily exacerbate the underlying condition or increase symptoms in patients with the following: hyperthyroidism, Parkinson’s disease, diabetes, renal impairment. Epinephrine should be administered with caution in patients with these conditions, including elderly patients and pregnant women.

Most common adverse reactions are nasal discomfort, headache, rhinorrhea, dizziness, nausea, vomiting, throat irritation, nasal congestion, paresthesia, sneezing, upper respiratory tract congestion, epistaxis, rhinalgia, nasal dryness, dry throat, fatigue, and feeling jittery.

These are not all of the possible side effects of neffy. To report suspected adverse reactions, contact ARS Pharmaceuticals Operations, Inc. at. 1-877-MY-NEFFY (877-696-3339) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information for neffy.